Management: Indomethacin
The most appropriate management for this preterm infant with poor feeding, cyanosis, and a holosystolic machinery murmur is indomethacin (Option A). This clinical presentation is consistent with a hemodynamically significant patent ductus arteriosus (PDA), which requires closure rather than maintenance of ductal patency.
Clinical Reasoning
Understanding the Presentation
The "holosystolic machinery murmur" is the classic auscultatory finding of a PDA with left-to-right shunting. The poor feeding and cyanosis ("bluish discoloration") indicate hemodynamic compromise from excessive pulmonary blood flow through the patent ductus, leading to:
- Pulmonary overcirculation and potential pulmonary edema
- Decreased systemic perfusion
- Congestive heart failure symptoms
Why Indomethacin is Correct
Indomethacin is a prostaglandin synthesis inhibitor that promotes ductal closure 1. The American College of Critical Care Medicine guidelines specifically state that "the majority of infants with [patent ductus arteriosus] are treated medically with indomethacin, or in some circumstances with surgical ligation" 1.
The mechanism is straightforward:
- Indomethacin inhibits cyclooxygenase, reducing prostaglandin E2 synthesis
- Prostaglandin E2 maintains ductal patency by relaxing smooth muscle
- Blocking prostaglandin E2 allows the ductus to constrict and close 2
Indomethacin closes PDA effectively, with studies showing it promotes ductal closure significantly better than placebo (pooled RR 2.39,95% CI 2.05-2.78) 3.
Why Prostaglandin is Wrong
Prostaglandin E1 (alprostadil) maintains ductal patency - it does the exact opposite of what this patient needs 4, 5. Prostaglandin is indicated only in "ductal-dependent" congenital heart lesions where systemic or pulmonary blood flow depends on the ductus remaining open, such as:
- Critical aortic stenosis or coarctation (ductal-dependent systemic circulation)
- Pulmonary atresia or critical pulmonary stenosis (ductal-dependent pulmonary circulation)
- Transposition of the great arteries (ductal-dependent mixing)
The AHA/ATS guidelines note that "Prostaglandin E1 may be considered to maintain patency of the ductus arteriosus" only in specific scenarios like congenital diaphragmatic hernia with suprasystemic pulmonary hypertension or RV failure 6.
Critical Distinction: When to Use Each
Use Indomethacin when:
- PDA is causing hemodynamic compromise (this case)
- Left-to-right shunting through the ductus
- Signs of pulmonary overcirculation or heart failure
- Preterm infant with respiratory distress syndrome and PDA
Use Prostaglandin when:
- Ductal-dependent congenital heart disease
- Need to maintain pulmonary blood flow (e.g., pulmonary atresia)
- Need to maintain systemic blood flow (e.g., critical coarctation)
- Need to maintain mixing (e.g., transposition)
Important Caveats
Timing of administration matters: Indomethacin should be given intravenously by syringe pump over at least 30 minutes to minimize adverse effects on cerebral, gastrointestinal, and renal blood flow 2.
Monitor for renal effects: Approximately 10-15% of patients experience an increase in serum creatinine ≥0.5 mg/dL after indomethacin, though this typically resolves within one week of cessation 2. The FDA label confirms risks of "renal dysfunction or failure" 7.
Contraindications to indomethacin include 7:
- Active bleeding (especially intracranial or GI)
- Thrombocytopenia
- Necrotizing enterocolitis
- Significant renal impairment
Common pitfall: In large premature infants with respiratory distress, always rule out ductal-dependent congenital heart disease before attempting pharmacologic ductal closure 5. However, the machinery murmur in this case confirms left-to-right shunting through a PDA, not a ductal-dependent lesion requiring right-to-left flow.